Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ:NRSN)

0.8843 -0.1157 (-11.57%)
Streaming Delayed Price Updated: 1:23 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeuroSense Therapeutics Ltd. - Ordinary Shares

News headline image
NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads
NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads 
Via News Direct
Topics Regulatory Compliance
News headline image
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
From Market News Alerts
Via Business Wire
News headline image
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
From PESG Research
Via Business Wire
News headline image
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
Via ACCESSWIRE
News headline image
NeuroSense Therapeutics (NASDAQ: NRSN) Shares Positive Final Results From Alzheimer’s Disease Biomarker Study
NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company, which is focused on the research and development of treatments 
Via Spotlight Growth
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.